Stocks Rise for BioTech Allied With Major Drugmakers (Japan)
This article was originally published in PharmAsia News
Several Japanese biotech companies have gotten a major investment boost of late. The financial windfall comes from a mixture of promising experimental treatments and partnerships with pharmaceutical heavyweights. First off the mark was Japan Tissue Engineering Co. The company got a major break on Oct. 3 when the Japanese Health Ministry gave it the green light to sell cultured skin samples to treat burn wounds. On the same day, Onccotherapy Science Inc. saw heightened investor interest thanks to speculation of a promising new cancer vaccine in development. AnGes MG Inc. and Sosei Group Corp. also saw massive spikes in their earnings between September and October. Experts say their fortunes were helped largely by partnerships with major drug makers. AnGes works with top Japanese firm Daiichi Sankyo, while Sosei partners with Swiss-based international giant Novartis AG. (Click here for more - May Require Paid Subscription
You may also be interested in...
White House and HHS are increasing pressure on FDA Commissioner Hahn to clear Pfizer and Moderna’s COVID-19 vaccines as soon as possible – potentially skirting the advisory committee process. The move is leaving a last-minute political stain on a regulatory process the FDA fought hard to keep science-based and could foster a new wave of vaccine hesitancy amongst the American public.
Two physicians experienced in agency affairs and operations, former commissioner David Kessler and former principal deputy commissioner Joshua Sharfstein, are reportedly finalists to head Biden’s FDA.
Operation Warp Speed will hold back initial shipments to ensure two-dose regimens can be completed; 15 December is ‘chalk’ target date for emergency authorization of Pfizer vaccine, OWS’ Gustave Perna says, calling it only a projection that does not impinge on FDA authority. Sending only half shipments also eases burden on cold shortage capacity at state and local level, he says.